eras-601,cetuximab,pembrolizumab
merck,eli lilly,erasca
['flagshp-1', 'cetuximab', 'eras-601', 'solid tumor']
erasca presents promising initial phase 1b dose escalation data from flagshp-1 for eras-601 plus cetuximab in patients with advanced solid tumors at the 2023 aacr annual meeting $eras 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2